Humanigen Announces Exploration of Potential Rights Offering
October 15, 2019 08:00 ET
|
Humanigen, Inc
BURLINGAME, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Humanigen, Inc., (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on the development of next generation CAR-T and other...
New ‘Blood Advances®’ Publication Supports Humanigen’s GM-CSF Neutralization Strategy with Lenzilumab in GvHD
October 08, 2019 08:00 ET
|
Humanigen, Inc
GM-CSF from the donor T cells initiates a cascade that drives lethal GvHDWithout GM-CSF signaling, there was a significant reduction in acute GvHDProvide a logical rationale to administer lenzilumab...
Humanigen, Inc. to Webcast Live at VirtualInvestorConferences.com October 10th
October 07, 2019 08:00 ET
|
Humanigen, Inc
BURLINGAME, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Humanigen, Inc., (HGEN) (“Humanigen”) a clinical stage biopharmaceutical company focused on the development of next generation cell and gene...
Humanigen Secures Exclusive Worldwide License for the Prevention of GvHD through GM-CSF Neutralization from the University of Zurich
July 22, 2019 08:00 ET
|
Humanigen, Inc
Expands Humanigen’s extensive intellectual property portfolio to include prevention of Graft-versus-Host Disease (GvHD)Strengthens Humanigen’s leadership position and platform in granulocyte...
Humanigen Secures Exclusive Worldwide License to Gene-Editing Technology from Mayo Clinic to Improve CAR-T
July 02, 2019 08:30 ET
|
Humanigen, Inc
Expands Humanigen’s intellectual property portfolio to include gene-edited CAR-T cellsBuilds and further strengthens Humanigen’s leadership position in GM-CSF neutralization GM-CSF neutralization has...
Humanigen to Present at the Jefferies 2019 Healthcare Conference
June 03, 2019 08:00 ET
|
Humanigen, Inc
BURLINGAME, Calif., June 03, 2019 (GLOBE NEWSWIRE) -- Humanigen, Inc., (HGEN) (“Humanigen”) a biopharmaceutical company focused on the development of its proprietary Humaneered® monoclonal...
Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (axicabtagene ciloleucel) With lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
May 31, 2019 08:31 ET
|
Humanigen, Inc
SANTA MONICA, Calif. and BURLINGAME, Calif., May 31, 2019 (GLOBE NEWSWIRE) -- Kite, a Gilead Company (Nasdaq: GILD) and Humanigen, Inc., (HGEN) announced today the formation of a clinical...
Publication in blood® Highlights Potential for GM-CSF Neutralization as a Solution for CAR-T Induced Neurotoxicity
May 16, 2019 17:00 ET
|
Humanigen, Inc
Severe neurotoxicity (NT) is a negative prognostic factor for overall survival with chimeric antigen receptor T-cell (CAR-T) therapyProlonged exposure of corticosteroids for severe NT may negatively...
Humanigen Announces Preliminary Results From Ifabotuzumab Phase I Study Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting
April 01, 2019 08:00 ET
|
Humanigen, Inc
Study Demonstrates that Dosing with Ifabotuzumab Results in Rapid, Specific and Reproducible Targeting of the Tumor Microenvironment in Patients with Glioblastoma Multiforme (GBM) Imaging Changes...
Humanigen Data Presented at the 2019 National Comprehensive Cancer Network (NCCN) Annual Conference Demonstrates Potential to Improve the Efficacy of CAR-T Therapy
March 21, 2019 17:00 ET
|
Humanigen, Inc
Enhanced anti-tumor activity, improved overall survival, and improved durability of response with a reduced rate of relapse observed with GM-CSF neutralization Lenzilumab (an anti-GM-CSF monoclonal...